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Objective: To investigate the psychosocial implications for families whose infant was identified as a cystic
fibrosis carrier by newborn screening.
Design: Prospective psychosocial assessment.
Setting: Primary care.
Respondents: Study: (a) families of an affected infant identified by screening (n = 9); (b) families of a
carrier infant identified by screening (n = 10). Control: group of mothers from the general population
(n = 82).
Interventions: Questionnaires and semistructured interviews.
Main outcome measures: Attitude to screening, assessments of the mother/baby relationship, anxiety,
wellbeing.
Results: All families were in favour of screening, with no evidence that the mother/baby relationship,
anxiety or wellbeing had been adversely affected. Parents, however, did identify problems in terms of the
service delivery protocol and genetic counselling practice.
Conclusion: Six months after disclosure, carrier identification was not perceived by parents to be
problematic.
N
ewborn screening for cystic fibrosis (CF) has been
possible since 1979 but remains controversial because,
although many paediatricians see value in earlier
prophylactic interventions, these have not yet been shown,
under trial conditions, to provide substantial long term
benefits.1
Currently in the United Kingdom, about 20% of newborns
are screened for CF (Northern Ireland, Wales, and parts of
England), but in April 2001 Yvette Cooper, Minister for Public
Health, announced that, subject to advice from the National
Screening Committee, screening would be extended to all
areas of England.2 Screening has also been proposed for
Scotland.3
All screening protocols assay immunoreactive trypsinogen
in dried blood spots as the primary test. Approximately 0.5%
of babies will have immunoreactive trypsinogen levels above
a threshold value, but only 1 in 12 of these will be affected. To
reduce this high false positive rate, most laboratories have
refined the screening process by introducing mutation
analysis on the original blood sample. This inevitably
identifies some healthy carrier infants. The population with
an abnormal immunoreactive trypsinogen level is enriched
with carriers and contains twice the number that could be
expected (unpublished Welsh data). The number of carriers
identified will depend on the range of mutations included in
the analysis, but will be about one case for each affected
infant detected.
The identification of healthy carrier infants is seen by some
health professionals as undesirable because of its potential
for early stigmatisation4 and disruption to the mother/baby
relationship.5 Some policy makers, both in the United
Kingdom and abroad, regard such identification as a major
problem, and this is impeding the wider introduction of CF
screening (R J Pollitt, personal communication, 2002).
This paper reports the findings of a small pilot study
carried out in 1999 to investigate the psychosocial implica-
tions for families with an abnormal screening result, in
particular, families whose infant was identified as a carrier.
METHODS
During the research period, screening samples were received
from 32 090 babies; 32 034 were screened for CF; 56 families
declined the test. When screening for CF was introduced in
Wales, an initial protocol for service delivery was developed
drawing on our experience in screening for Duchenne
muscular dystrophy.6 This protocol for the follow up of
abnormal results is detailed in the box. There were 19
abnormal results, after sweat testing (nine were identified as
having CF, and 10 as carriers). All the families agreed to join
the psychosocial study. In addition, a group of mothers from
the general population (n = 82) was drawn to provide
control data where appropriate.
To investigate the psychosocial implications of newborn
screening for CF, three research interventions were used.
Firstly, an assessment by the health visitor of the mother’s
responses to her baby on five dimensions: feeding, interest,
response, speech, and touch.7 The assessment was made
before the query about CF was raised and one month later.
Each dimension was scored from 0 to 2, giving a cumulative
score ranging from 0 to 10. Secondly, a structured ques-
tionnaire was completed by mothers six months after sweat
testing. The following measures were included:
(a) Attitude to screening (options given were in favour,
against, undecided).
(b) Rejection index8: mothers were asked to score the
statement that explored potential rejection (‘‘I feel I want
to run away and leave my baby’’). The statement was scored
1 (strongly disagree) to 5 (strongly agree) giving a range of
1–5.
(c) Protection index8: mothers were asked to score
four statements that explored potential overprotection (feel-
ing protective, wanting to hug, watching closely, and not
trusting baby with others). Each statement was scored 1
(strongly disagree) to 5 (strongly agree) giving a range of
4–20.
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(d) Baby adjectives8: mothers were given a list of 14 adjectives
and asked to select as many as they thought best described
their baby. The adjectives were: doing well, healthy, placid,
responsive, alert, little, demanding, difficult, miserable, great,
lovely, fun, cuddly, and exhausting.
(e) Anxiety: mothers completed the six item short form of the
state scale9 10 which has a range of 6–24 with a normal range
of 6–12.
(f) Wellbeing: mothers completed the general health ques-
tionnaire (GHQ 12).11 The GHQ was scored conventionally
and has a range of 0–24 with a normal range of 0–4.
Data from the control group were available for items b, c, d,
and f.
Thirdly, a semistructured interview with each family
six months after sweat testing. The aim of the informal
interview was to explore the advantages and disadvantages of
newborn screening and parent’s experiences of the process.
The quantitative data were analysed using SPSS for
Windows version 10. Statistical analysis was carried out
using Kruskal-Wallis analysis of variance, t test, Mann-
Whitney, Wilcoxon, x2, and Fisher’s tests as appropriate. The
qualitative data were transcribed and then analysed to
identify critical themes. The two data sets were then
compared and combined. The results are reported with
particular reference to the implication for carrier families,
using the following headings: attitude to newborn screening,
infant carrier identification, adult carrier identification,
newborn screening protocol, and the family dimension.
RESULTS
Attitude to screening
All the families who had their baby identified as a carrier
(n = 10) were in favour of newborn screening. Typical
comments were:
‘‘…glad I know…I would rather know than not know’’
(051)
‘‘…sooner things come to light the better…at least we
know it’s in the family now.’’ (034)
‘‘In favour definitely, we can be aware of that for when
they start their family.’’ (042)
Carrier infant identif ication
Health visitor assessment of the mother/baby
relationship (FIRST scores)
There was no evidence of any significant change (Wilcoxon)
in the mother/baby relationship using the FIRST assessment
scores.
Rejection index, protection index, anxiety, and
wellbeing
No significant differences (t test, Mann-Whitney) were found
between the CF carrier cohort, the CF affected cohort, and the
control group (where appropriate) on the rejection index, the
protection index, anxiety scores, or wellbeing. It is interesting
to note, however, that, on the protection index, the affected
cohort scored higher than the other cohorts on the
statements about trusting their baby with others and
watching closely. This is perhaps a reflection of the fact that
their babies were symptomatic.
Table 1 gives the results of these measures.
Baby adjectives
There was no significant difference (x2, Fisher’s) between the
CF carrier cohort, CF affected cohort, and the control group in
their choice of baby adjectives, although fewer mothers in the
affected group chose the descriptor ‘‘healthy’’.
Qualitative data
The interview provided qualitative data on how the parents
talked about their baby now they were known to be a carrier.
During the thematic analysis, we searched for statements
that might indicate concerns that their baby’s identity had
been spoiled or that they anticipated future stigmatisation.
The parents’ accounts focused on three main issues. Firstly,
they all made reference to the fact that their baby was
‘‘perfectly healthy’’:
‘‘I knew with him being just a carrier he wouldn’t be ill’’
(042)
‘‘It didn’t really bother me at all, knowing that they were
healthy (047)
‘‘No I’m quite satisfied she’s not going to suffer from it’’
(046)
One family had taken their knowledge one step further:
‘‘He was well clear, he was a carrier but the genes were
recessive’’ (036)
In two families the adult carrier had made the connection
between their own continued health and the fact their baby
was going to be the same:
‘‘I’ve lived a normal life up until now and it’s not affected
me so it shouldn’t affect him’’ (047)
Secondly, the way the families talked about their baby’s
carrier status indicated that it caused them very little
concern. They talked about them as being ‘‘just a carrier’’
or ‘‘only a carrier’’:
‘‘He hasn’t got it so it’s put to the back of my mind’’ (036)
‘‘As far as we’re concerned it’s finished–I know he’s a
carrier…’’ (051)
‘‘I wasn’t that concerned…’’ (046)
‘‘…the pressure was off…I know that he is perfectly
fine…’’ (042)
‘‘I don’t give it a second thought…’’ (044)
Thirdly, they were all aware that at some point in the
future they would have to pass the information on:
‘‘The thing is you’re aware of it but for them you are
talking 15 or 20 years ahead and there will be better
forms of identification then’’ (034)
‘‘…she was only a carrier but we will need to let her know
at a certain age so she is more aware than I was’’ (041),
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There was also a feeling that at some point the young
person would have to take their own decisions:
‘‘I mean they may fall in love with someone who is also a
carrier… but it’s up to them at that point…that’s their
choice, not mine…that’s their life…it’s up to them and my
other children to decide what they want to do.’’ (036)
In summary, there was no evidence that the mother/baby
relationship had been affected by the carrier identification or
that carrier status was seen by parents as a problem in terms
of spoiled identity.
Adult carrier identification
The inevitable consequence of a baby being identified as a CF
carrier is that at least one parent is also a carrier. In this
study, six of the fathers were carriers and four of the
mothers. One mother recalled that when she first heard she
had been a ‘‘bit apprehensive’’ (034), another said that
initially she had been ‘‘gutted’’ (046). By the six month
interview, however, all the carriers were very philosophical
about their status:
‘‘Of course it means something but it’s not particularly
good or bad’’ (041)
‘‘It doesn’t affect me, it’s not an illness, I just carry on doing
my normal thing’’ (042)
‘‘It’s just the same as blue eyes, tall, short whatever, I
didn’t feel anything was bad’’ (044)
‘‘It’s just one of those things I have, its latent, its just lying
there…’’ (036)
For some carriers there was recognition they were not alone:
‘‘There are so many people who are carriers, it’s going to
come up time and time again.’’ (043)
‘‘I am sure there are literally hundreds of people who are
carriers, we’re just not aware of it.’’ (047)
There were two parents, however, who felt some guilt
about what they might have passed on. One father, although
he was not at all concerned about his own carrier state, said:
‘‘I felt uncomfortable, I’d passed something on to my son’’
(044)
It was the same for one mother:
‘‘You don’t like to think you are going to pass anything
awful to a child, I don’t feel bad about it now but I did have
this guilty feeling…’’ (034)
For other carriers there was no problem, one mother said:
‘‘…no I’ve got no guilt…I don’t blame my mother or father
for passing it on to me…it’s blameless isn’t it. They say it’s
the most common hereditary…goodness knows what else
we’ve got laying dormant… (036)
Newborn screening protocol
When parents were asked about the emotions they had felt at
that time, they talked about ‘‘feeling afraid’’ and ‘‘being
worried’’; one mother described it ‘‘like a dark cloud’’ (036),
another talked about being ‘‘in a state’’ (043), and another
referred to it as a ‘‘shock’’ (041). One distressing aspect for
some of the families with a carrier infant was the way they
had been told that there was a query on the CF test.
Further analysis of the transcripts identified three specific
areas where anxieties had been unnecessarily raised because
of the way the case had been handled. Firstly, on four
occasions two health professionals had called on the family
to raise the query: the health visitor and a specialist CF nurse.
For these families, this visit by a specialist to talk about CF
just confirmed their worst fears:
‘‘I was under the impression that he really had it. Having a
counsellor come all the way from (name of town) to go
through it all before having the sweat test, I was convinced
that he had it’’ (042).
One mother had been told the information over the
telephone by her general practitioner, and another mother
first learnt about the query when she received a card giving
her an appointment with a paediatrician five days later, her
health visitor having not been informed. Although a protocol
was in operation during the research period, for various
reasons, it was not always followed.
Secondly, whether the families had been visited by their
health visitor or the specialist nurse, they had been given
details about CF. In some cases they had been left with a CF
Trust leaflet:
‘‘So I read the leaflet and automatically thought the worst.
It was saying what CF was…’’ (047)
‘‘She just explained a bit about what the disease was–so
we got the basics… all I could see was the fact that there
was something seriously wrong with him’’ (051).
Thirdly, most families recalled the negative language that
had been used:
‘‘It’s just the shock of someone telling you there is
something wrong’’ (041)
‘‘She just said that the test had come back positive’’ (042)
Table 1 Median and interquartile range for FIRST
scores, rejection index, protection index, anxiety, and
wellbeing
Measure
Carrier cohort
(n = 10)
Affected cohort
(n = 9)
Control
(n = 82)
FIRST scores
(normal range 8–10)
Before 10 (8.3–10) 10 (8.5–10)
After 9.5 (8.3–10) 10 (10–10)
Rejection index
(range 1–5) 1 (1–1) 1 (1–1) 1 (1–2)
Protection index
(range 4–20) 10.5 (6–12.3) 14 (13–17.5) 13.5 (12–16)
Anxiety (normal
range 6–12) 11 (9.5–12.3) 11 (10–14.5)
Wellbeing (GHQ)
(normal range 0–4) 1 (0–3.5) 3 (0–8) 2.5 (1–5)
GHQ, General health questionnaire.
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For one mother it had been the approach that had been
hard to cope with:
‘‘I was not happy with the way it was put across…. they
just showed no sympathy, no warning, they just blurted it
out’’ (046).
The family dimension
The identification of any genetic disease has family implica-
tions. In this study all of the carrier families were offered and
accepted genetic counselling. There were, however, two
particular areas that they highlighted as being problematic:
the testing of their other children and the difficulty of telling
family members.
Testing other children
The study has shown that carrier status, per se, caused little
concern to the families, either in terms of the infant or adult
carrier. It was therefore difficult for parents to understand
why clinical geneticists were reluctant to test their other
children. One mother said:
‘‘They said if he wanted it done when he was older, he
could, and his partner as well, but they wouldn’t do it
now…. They said you’re better off doing it when he’s older
but I would rather know now than later on’’ (043)
It was the same for another mother:
‘‘Well the letter said that I could have them tested when
they were older but I would rather know now when they’re
younger’’ (046)
One mother, who had been worried about her daughter,
was told she could only have her tested if she and her
husband were both carriers.
The extended family
Most families talked at length about passing the news to
other family members. The language, however, reflected
feelings of ‘‘obligation’’, with the use of phrases such as: ‘‘it
meant contacting’’, ‘‘I had to pass information on’’, ‘‘we felt
we should’’, ‘‘it’s our responsibility to tell’’. In some cases
making these contacts had been the most difficult part of the
whole event. Brothers, step-brothers, sisters, and step-sisters,
some of whom were pregnant when the carrier status had
been identified, needed to be told. For one grandmother, the
concern was not her own potential carrier status, but the fact
that she might have to contact her ex-partner, the father of
the index carrier:
‘‘She’s not very worried herself but she doesn’t want to
contact him unless she has to…that’s the only thing she’s
worried about.’’ (046)
In another family, it had led to difficulties between the
grandparents. For another, the brother, having been told,
would not talk about it, and his carrier sister felt a distance
had developed between them not previously there.
One mother said:
‘‘We thought we were under an obligation to be tested for
members of the family more than anything else…it was still
a family sort of thing…and I just feel that we got no
support…it was just very difficult…the emotional aspect of
it…’’ (034)
Another couple felt that they did not have enough
information and were struggling to find the right words:
‘‘I knew I had to tell my Dad and he rang my brothers who
live away… we all met up and we tried to talk to them but
it was difficult getting it through…I am sure we put both
feet in it somewhere…missed out relevant points…’’ (044)
It was interesting that, for many families, discussion about
carrier issues in the wider family proved to be most
problematic consequence of newborn screening.
DISCUSSION
This small study has indicated that all the families who had
their baby identified as a carrier were in favour of newborn
screening, and there was no evidence that the mother/baby
relationship, maternal anxiety, or wellbeing had been
adversely affected. These findings were supported by the
qualitative data, with no evidence that they were either
concerned about the health of their baby or possible future
stigmatisation. This finding is different from that of Baroni
et al.5 In their study of families, one year after a carrier result,
they report that, although parents had low stress scores, they
showed a degree of defensiveness which could reflect
‘‘hypervigilance and emotional repression’’.
Over the past 15 years, there has been extensive research
looking at the psychosocial implications of carrier screening
for adults. Most studies have concluded that, when a carrier
is identified, there are raised anxieties, but within one year
these have dissipated.12–14 Adults in this study were different,
they had not chosen to have carrier screening and were
therefore not expecting a result that would implicate them.
Our findings are in line with other studies, in that after
six months there was no evidence that any of the parents
were unduly concerned.
This study, however, has highlighted new findings in terms
of problems in two areas of service delivery: the protocol used
by health professionals for raising the query with families
and the delivery of genetic counselling. Firstly, some families
reported that they had experienced unnecessary anxiety
because of the way they had been told there was a query on
the newborn screening test. This study has been valuable in
identifying those areas where the protocol for CF needs some
modification and more rigorous implementation. In the case
of those families where a single mutation is found we would
recommend that:
(1) the family are visited to be told about the query by a
member of their primary healthcare team who is known to
them and is not accompanied by a specialist CF nurse who
they have not met before;
(2) the health professional concerned takes great care to use
positive language and be reassuring;
(3) at the initial meeting any details about CF as a disease are
kept to a minimum.
Secondly, with respect to the delivery of genetic counsel-
ling services, parental accounts highlighted their concerns
about being unable to ascertain the carrier status of their
other children and the problems they faced in talking about
carrier issues to other members of their family. The Working
Party of the Clinical Genetics Society (UK)4 concluded that
carrier testing of children should be deferred until they are of
an age to be fully involved in the decision. The feedback from
the families would indicate that this is current practice in
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departments of medical genetics. In terms of carrier testing
therefore parents are receiving a double message. From
genetics, they are told it is not policy to disclose children’s
carrier status to parents whereas, from newborn screening, it
is apparently quite acceptable and our research indicates that
the information has not caused them any distress. Clearly
this is an area of policy that needs clarification.
The second area some parents found difficult to handle
was the expectation they would initiate discussions with
their extended family. It is interesting that the carrier
identification of an infant and its parent seemed to raise
minimal concerns whereas, for some, talking about it to other
family members was problematic. Fanos and Johnson,15 in
their study of CF siblings, and Williams and Schutte16 and
Claes et al17 report similar findings. It would seem as if the
discomfort is caused because a genetic diagnosis has the
potential to bring to the surface dysfunctional family
relationships and create new tensions. This problem, how-
ever, is not specific to newborn screening for CF, and we
would recommend that a protocol is developed to cover all
situations where cascade testing takes place. The protocol
should ensure that members of an index family are not left
unsupported as the main information givers and are provided
with a short information leaflet which they can pass on to
their relatives. This information sheet should contain details
about the condition, the purpose of cascade screening,
together with contact names and telephone numbers. Such
a factsheet is already available from the Cystic Fibrosis
Trust.18
Conclusion
This small study has provided important preliminary data
on the psychosocial implications of carrier identification
as a result of newborn screening. The data indicate
that, six months after disclosure, carrier identification
was not perceived by parents to be problematic. There
was, however, evidence of areas where healthcare policy
needs clarification and health professionals’ practice needs
modification.
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Protocol for the follow up of an abnormal
newborn screening test for CF
1. Contact primary healthcare team (health visitor and
general practitioner) to inform them, to discuss health of
baby, and arrange for them to talk to family about having
baby sweat tested.
2. Inform the secondary healthcare team (paediatrician and
specialist CF nurse), arrange date for sweat test, and
suggest liaison between specialist nurse and health visitor.
3. Family told about the query and the arrangements for the
sweat test.
4. Sweat testing and result given by paediatrician on the
same day, implications discussed.
5. Referral to medical genetics for counselling offered.
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